Expect to See DOACs for Venous Thromboembolism Due to Cancer

June 2020

You'll continue to see a shift toward direct oral anticoagulants (Eliquis, etc) for cancer-associated venous thromboembolism (VTE).

We're used to seeing these patients on a low-molecular-weight heparin (LMWH), such as enoxaparin...or warfarin as an alternative.

But evidence with DOACs is stacking up for VTE due to cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote